💊 药物 A-Z 🧬 靶点 🛠 工具 📚 指南
全部药物 药物分类 治疗领域 不良反应
指南 术语表 时间轴
药物比较 药物旅程 药物家族
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Tofacitinib

CHEMBL221959 Phase 4 已批准 Small molecule
Half-Life
3.2 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
312.4 g/mol
LogP
1.5
Phase
4

This oral JAK inhibitor is used to treat moderate to severe rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and atopic dermatitis in patients who have not responded adequately to other treatments. It works by blocking Janus kinase (JAK) enzymes that transmit inflammatory signals inside immune cells. Due to risks including serious infections, blood clots, and cardiovascular events, it is typically reserved for patients who have not responded to safer therapies.

分子量

312.3700 g/mol

LogP

1.50

TPSA

88.90 Ų

Lipinski 五规则

符合

治疗领域

Age-Related Macular Degeneration Respiratory Disease Pain Management Rheumatoid Arthritis Migraine Generalized Anxiety Disorder Inflammatory Bowel Disease Psoriasis Systemic Lupus Erythematosus Lymphoma Transplant Medicine Atopic Dermatitis Chronic Pain

药物分类

L — L - Antineoplastic and Immunomodulating Agents

作用机制

Pan-JAK inhibitor with preference for JAK1 and JAK3 blocking pro-inflammatory cytokine signaling.

Pharmacokinetics (PK)

Half-Life 3.2 hours

Pharmacodynamics (PD)

机制

Pan-JAK inhibitor with preference for JAK1 and JAK3 blocking pro-inflammatory cytokine signaling.

二维结构

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12

                

                

                
                

                    
InChI

                    
InChI=1S/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13+/m1/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C16H20N6O

                    

                    
                    

                        
HBD / HBA

                        
1 / 5

                    

                    
                    

                        
可旋转键数

                        
3

                    

                    
                    
                    

                        
重原子数

                        
23

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
常见问题

                

                    
                    

                        
                        

                            
This oral JAK inhibitor is used to treat moderate to severe rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and atopic dermatitis in patients who have not responded adequately to other treatments. It works by blocking Janus kinase (JAK) enzymes that transmit inflammatory signals inside immune cells. Due to risks including serious infections, blood clots, and cardiovascular events, it is typically reserved for patients who have not responded to safer therapies.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Pan-JAK inhibitor with preference for JAK1 and JAK3 blocking pro-inflammatory cytokine signaling.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Tofacitinib: Half-life: 3.2 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Tofacitinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            
            

                
                
                    ADME Journey →
                
                
                
            

            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Methotrexate
                            Small molecule
                        
                        
                        
                            Tamoxifen
                            Small molecule
                        
                        
                        
                            Cyclosporine
                            Protein
                        
                        
                        
                            Tacrolimus
                            Small molecule
                        
                        
                    

                

                

                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL221959.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 9926791.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
医疗免责声明

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.